ART26.12

FABP5 Inhibitor Program for Breast and Prostate Cancers

Scientific and Clinical Validation

  • Fatty Acid Binding Protein 5 (FABP5) Inhibitor with high potency and selectivity
  • FABP5 is an intracellular protein that chaperones lipids including endocannabinoids and fatty acids
  • In vivo efficacy in models of pain, anxiety, and inflammation through mechanisms involving the endocannabinoid system
  • In vivo efficacy in animal models of prostate cancer through mechanisms involving the regulation of pro-tumoral and pro-metastatic proteins
  • FABP5 is a validated target in breast, prostate and cervical cancers, and is implicated in many other cancer types

Learn more about ART26.12

Formulation and Intellectual Property

  • Three patents issued
  • 14 patent applications pending, with two additional planned

Opportunity

  • Prostate cancer
  • Breast cancer
  • Other cancers
  • Pain/Inflammation
  • Anxiety/PTSD

What is FABP5?

Fatty acid binding proteins (FABPs) are proteins within a cell that help to transport lipophilic (fat loving), hydrophobic (water fearing) molecules around intracellular compartments.  There are several different types of FABPs, and FABP5 is one of the main transport mechanisms for endocannabinoids, fatty acids and their derivatives. Fatty acids like anandamide (AEA) are bound within the center of the FABP molecule, which acts like a barrel around the fatty acid molecule.

References:

  1. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. Zilbermint MF, Dobs AS, Future Oncol. 2009 Oct; 5(8):1211-20;
  2. Data from Market Intel Reports 2016 as quoted in Innovus Pharma to Enter the Oncology Supportive Care Market With an Exclusive License to Two GRAS-Listed OTC Compounds for Cachexia and Muscle Growth and Repair From the University of Iowa Research Foundation. Innovus Press Release June 6, 2017, ex-US estimate based upon market forecast model from US sales figures;
  3. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. Advani, Shailesh M et al., BMC cancer vol. 18,1 1174. 27 Nov. 2018, doi:10.1186/s12885-018-5080-4;
  4. Sánchez‐Lara K, Ugalde‐Morales E, Motola‐Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr 2013;109:894‐7,
  5. Management of Cancer Cachexia: ASCO Guideline, May 2020;
  6. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.: CD004310.
  7. https://www.ncbi.nlm.nih.gov/pubmed/22249824
  8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027162/
  9. Source: AstraZeneca, adMare. Data on file
  10. FABP5 protein structure image by Emw – Own work, CC BY-SA 3.0